Filing Flows › 4D Molecular Therapeutics (FDMT) › Q2 2026 › vs Q2 2025
4D Molecular Therapeutics (FDMT) Q2 2026 vs Q2 2025 (year over year)
4D Molecular Therapeutics's revenue rose $3.8M (252×) from $15K in Q2 2025 to $3.8M in Q2 2026.
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.8M | $15K | $3.8M | 252× |
| Other income, net | $4.1M | $4.8M | −$709K | -15% |
| Net loss | $72.9M | $54.7M | $18.3M | +33% |
| Costs & expenses | $80.8M | $59.5M | $21.3M | +36% |
| Operating costs | $80.8M | $59.5M | $21.3M | +36% |
| Research & development | $68.3M | $48.0M | $20.3M | +42% |
| General & admin | $12.5M | $11.5M | $1.0M | +9% |
| Operating cash sources | $77.2M | $49.5M | $27.7M | +56% |
| Depreciation & amortization | $1.3M | $1.2M | $114K | +10% |
| Share-based compensation | $5.9M | $5.0M | $926K | +19% |
| Cash used in operations | $70.0M | $43.4M | $26.6M | +61% |
| Net loss absorbed | $72.9M | $54.7M | $18.3M | +33% |
| Working capital & other | $4.2M | −$5.2M | $9.4M | — |
Questions
How much did 4D Molecular Therapeutics's revenue grow year over year in Q2 2026?
4D Molecular Therapeutics's revenue rose $3.8M (252×) from $15K in Q2 2025 to $3.8M in Q2 2026.